Background: Cancer-initiating cell (CIC) exosomes (CIC-TEX) are suggested reprogramming Non-CIC. Mode of message transfer and engagement of CIC-markers being disputed, we elaborated the impact of CD44v6 and Tspan8 on the response of Non-CIC.
Methods: Non-metastasizing CD44v6- and Tspan8-knockdown (kd) pancreatic cancer cells served as Non-CIC. CIC-TEX coculture-induced changes were evaluated by deep-sequencing and functional assays. Tumor progression was surveyed during in vivo CIC-TEX treatment.
Results: Deep-sequencing of CIC-TEX-cocultured CD44v6kd-Non-CIC revealed pronounced mRNA changes in signaling, transport, transcription and translation; altered miRNA affected metabolism, signaling and transcription. CIC-TEX coculture-induced changes in Tspan8kd-Non-CIC mostly relied on CIC-TEX-Tspan8 being required for targeting. CIC-TEX transfer supported apoptosis resistance and significantly promoted epithelial mesenchymal transition, migration, invasion and (lymph)angiogenesis of the kd Non-CIC in vitro and in vivo, deep-sequencing allowing individual mRNA and miRNA assignment to altered functions. Importantly, CIC-TEX act as a hub, initiated by CD44v6-dependent RTK, GPCR and integrin activation and involving CD44v6-assisted transcription and RNA processing. Accordingly, a kinase inhibitor hampered CIC-TEX-fostered tumor progression, which was backed by an anti-Tspan8 blockade of CIC-TEX binding.
Conclusions: This in depth report on the in vitro and in vivo impact of CIC-TEX on CD44v6kd and Tspan8kd Non-CIC unravels hub CIC-TEX activity, highlighting a prominent contribution of the CIC-markers CD44v6 to signaling cascade activation, transcription, translation and miRNA processing in Non-CIC and of Tspan8 to CIC-TEX targeting. Blocking CIC-TEX binding/uptake and uptake-initiated target cell activation significantly mitigated the deleterious CIC-TEX impact on CD44v6kd and Tspan8kd Non-CIC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425561 | PMC |
| http://dx.doi.org/10.1186/s13046-019-1129-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinct Origin of Claudin7 in Early Tumor Endosomes Affects Exosome Assembly.
Int J Biol Sci
April 2020
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany.
Article Synopsis
- * Claudin7 serves as a biomarker for gastrointestinal tumors and is involved in the composition and function of these microvesicles, with its behavior differing based on its palmitoylation status, which affects its localization and interaction with other cellular components.
- * Analysis of claudin7 in cancer cells revealed that its palmitoylated form enhances certain membrane signals and lipid metabolism, while the non-palmitoylated form aids in recruiting proteins for transport and metabolism, highlighting the importance of recognizing different microves
The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery.
J Oncol
August 2019
Tumor Cell Biology, University Hospital of Surgery, Heidelberg, Germany.
Article Synopsis
- Pancreatic cancer-initiating cells (PaCIC) express markers CD44v6 and Tspan8, which are important for their ability to metastasize, and reducing these markers can limit this capacity; however, exposure to exosomes from cancer cells can restore this capacity.
- Research involving deep sequencing and multiple analytical techniques shows that CD44v6 regulates Tspan8 and interacts with various signaling molecules, suggesting that these markers play a significant role in tumor progression.
- The study proposes that CD44v6, by partnering with Tspan8 and affecting mRNA processing, enhances tumor growth and metastasis through mechanisms involving both direct cellular functions and their impact on exosome-related pathways.
Exosomes, metastases, and the miracle of cancer stem cell markers.
Cancer Metastasis Rev
June 2019
Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Cancer-initiating cells (CIC) are the driving force in tumor progression. There is strong evidence that CIC fulfill this task via exosomes (TEX), which modulate and reprogram stroma, nontransformed cells, and non-CIC. Characterization of CIC, besides others, builds on expression of CIC markers, many of which are known as metastasis-associated molecules.
View Article and Find Full Text PDFClaudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells.
Int J Cancer
October 2019
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Article Synopsis
- Claudin7 (cld7) is identified as a marker for cancer-initiating cells (CIC) in gastrointestinal tumors, where knocking down cld7 reduces tumor progression.
- Tumor exosomes (TEX) from both CIC and cld7-knockdown (kd) cells were studied, revealing that cld7 plays a significant role in promoting tumor cell migration and metastasis, particularly through GEM-derived exosomes.
- CIC-TEX were found to initiate changes in protein and miRNA profiles in cld7kd cells, enhancing processes like invasion and lymphangiogenesis, and suggesting that RTK inhibitors could be a potential therapeutic strategy to counteract the influence of CIC-TEX on tumor progression.
Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming.
J Exp Clin Cancer Res
March 2019
Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Background: Cancer-initiating cell (CIC) exosomes (CIC-TEX) are suggested reprogramming Non-CIC. Mode of message transfer and engagement of CIC-markers being disputed, we elaborated the impact of CD44v6 and Tspan8 on the response of Non-CIC.
Methods: Non-metastasizing CD44v6- and Tspan8-knockdown (kd) pancreatic cancer cells served as Non-CIC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!